UroGen Pharma Ltd.: Business Overview, Financials & Competitive Analysis
UroGen Pharma Ltd. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Biotech cash burn story with compelling pipeline catalysts (UGN-102 FDA decision June 2025) offset by precarious balance sheet requiring successful commercialization. The company generated $96.52 million in trailing twelve-month revenue with an 87.95% gross margin, but exhibits a deeply negative net margin of -170.59%. Financial health is under scrutiny.
What is UroGen Pharma Ltd.'s industry? UroGen Pharma Ltd. (urogen.com) operates in Biopharmaceutical/Oncology - Urothelial Cancer Therapeutics. AskCyborg classifies UroGen Pharma Ltd. under Biopharmaceutical/Oncology - Urothelial Cancer Therapeutics in its company registry.
UroGen Pharma is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers, developing RTGel reverse-thermal hydrogel technology enabling sustained drug release. The company's ...
Cyborg Score thesis
Biotech cash burn story with compelling pipeline catalysts (UGN-102 FDA decision June 2025) offset by precarious balance sheet...
Read the full analyst-debate transcript →Get the Latest UroGen Pharma Ltd. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeUroGen Pharma Ltd. Overview
Pro stress-test →UroGen Pharma is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers, developing RTGel reverse-thermal hydrogel technology enabling sustained drug release. The company's flagship product Jelmyto targets non-surgical tumor ablation in non-muscle invasive urothelial cancer, with investigational candidate UGN-102 in pivotal development.
Strategic Profile
Pro stress-test →UroGen's RTGel platform is a proprietary sustained-release hydrogel technology designed to enable longer exposure of urinary tract tissue to medications, making local therapy a potentially more effective treatment option. The company recently secured a revised $250 million loan agreement with Pharmakon Advisors (signed February 26), providing $200 million to refinance existing debt and fund operations, with an additional $50 million available upon conditions.
Competitive Landscape
Pro stress-test →UroGen competes in the clinical-stage biopharmaceutical space focused on non-surgical treatment options for urological cancers. Primary competitors include larger oncology focused companies (Merck, Janssen) developing bladder cancer therapies and specialty biotech firms using alternative local delivery technologies.
Industry Context
UroGen Pharma Ltd. operates in Biopharmaceutical/Oncology - Urothelial Cancer Therapeutics.
Key facts
Founded: 2004 · Headquarters: Princeton, New Jersey, USA · Employees: 201 · Revenue: $96.5M · Market cap: $1.02B